| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | ||
| Market Cap | 119.94 Cr. | |
| Enterprise Value(EV) | 122.85 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.22 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 30.30 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 33.43 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 2.91 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 2.30 | Calculated using Price: 6.70 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 17.90 Cr. | 179,009,534 Shares |
| FaceValue | 1 | |
| About Gennex Laboratories Ltd. | ||
| Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements. | ||
| 1 Day |
|
+1.93% |
| 1 Week |
|
+3.47% |
| 1 Month |
|
+7.37% |
| 3 Month |
|
+17.70% |
| 6 Month |
|
+13.41% |
| 1 Year |
|
+5.06% |
| 2 Year |
|
+15.32% |
| 5 Year |
|
+135.40% |
| 10 Year |
|
+696.51% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 0.82 | 2.57 | 8.69 | 9.14 | 2.67 | 6.75 | 5.32 | 10.66 | 9.35 | |
| Return on Capital Employed (%) | 3.63 | 4.57 | 11.78 | 11.61 | 6.31 | 10.49 | 8.32 | 13.18 | 11.78 | |
| Return on Assets (%) | 0.54 | 1.66 | 5.77 | 5.94 | 1.68 | 4.34 | 3.40 | 6.95 | 6.16 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 25 | 26 | 28 | 31 | 32 | 34 | 36 | 40 | 44 | 46 | |
| Non Curr. Liab. | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | ||
| Curr. Liab. | 12 | 13 | 12 | 17 | 18 | 17 | 21 | 19 | 24 | 18 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 74 | |
| Non Curr. Assets | 23 | 22 | 23 | 23 | 23 | 23 | 22 | 23 | 22 | 22 | |
| Curr. Assets | 16 | 17 | 19 | 26 | 28 | 29 | 35 | 36 | 47 | 52 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 74 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 35 | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 68 | |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Total Income | 35 | 32 | 39 | 42 | 45 | 57 | 57 | 60 | 63 | 70 | |
| Total Expenditure | -33 | -30 | -34 | -37 | -42 | -52 | -52 | -53 | -56 | -63 | |
| PBIDT | 2 | 2 | 4 | 5 | 3 | 5 | 4 | 7 | 7 | 7 | |
| Interest | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Exceptional Items | 0 | 0 | 0 | 0 | |||||||
| PAT | 0 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 4 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 0 | 0 | 3 | 0 | 3 | 2 | -2 | -1 | 7 | |
| Cash Fr. Inv. | -1 | -1 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | |
| Cash Fr. Finan. | 0 | 0 | 0 | -2 | 1 | -2 | 1 | 0 | 2 | 2 | |
| Net Change | -2 | 0 | 0 | 0 | 0 | 0 | 2 | -2 | 0 | 7 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 8 |
|
Thu, 01 Jun 2023
License To Manufacture For Sale(Or For Distribution) Of Drugs Received Deccan Remedies Limited (Subsidiary Company) From Drug Control Administration Of Government Of Andhra Pradesh We hereby inform you that the Subsidiary of the Company M/s. Deccan Remedies Limited received license to manufacture for sale (or for distribution) of drugsfrom Drug Control Administration of Government of Andhra Pradesh on May 29 2023 licence copy enclosed to this letter. The license shall be valid for a period of 5 Years i.e. 29-05-2023 TO 28-05-2028.list of licence to manufacture for sales (or for distribution) drugs/products List Enclosed :The above said information is intimating Pursuant Reg.30 of SEBI (LODR) Regulations 2015.Request to consider the information on records and oblige the same. |
|
Thu, 01 Jun 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Newspaper Publication on Audited (Standalone & Consolidated) Financial Results for the 4th Quarter and Year Ended March 31 2023 announced by the Board of Directors in its meeting held on Tuesday May 30 2023. Financial results had been published in both Business Standard and Andhra Prabha on Thursday June 01 2023.We request you to take the above information on record and acknowledge receipt of the same. |
|
Thu, 01 Jun 2023
Additional Details Regarding Time Of Commencement And Conclusion Of Board Meeting Of The Company Held On May 30 2023; This has reference to your email dated 01.06.2023 regarding Additional Details Required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations 2015.In continuation to our intimation dated 30.05.2023 with reference to the Outcome of the Board Meeting regarding Audited Standalone and Consolidated Financial Results for the 4th quarter and year ended 31.03.2023 please note that the said Board Meeting had commenced at 16.30 p.m. on 30.05.2023 and concluded at 2.10 a.m. on 31.05.2023.This is for your kind information and records. |
| Fri, 02 Jun 2023 |
High Increase in 1 Month
|
High Increase in 3 Months
|
High Increase in 5 Years
|
CCI Overbought Zone
|
Bullish Harami Cross
|
Equities
M.F.
Sectors
StockEdge Social